Closed · RFA-CA-21-054 · CFDA 93.394;93.396 · Discretionary
Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $1M
- Award range
- Closed
- Status
- November 2, 2021
- Close date
- -
- Expected awards
The verdict
Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $1,000,000. Future funding cycles may be published under the same CFDA number.
- up to $1M
- award range
- Closed
- application status
- 93.394;93.396
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed) - is cataloged under number RFA-CA-21-054 and tied to CFDA assistance listing 93.394;93.396, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on August 31, 2021. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Up to $1,000,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on November 2, 2021. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $1,000,000
Close Date
November 2, 2021
Posted
August 31, 2021
Instrument
Cooperative Agreement
Description
The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The FOA will utilize the U54 (Specialized Center--Cooperative Agreements) activity code. Each TBEL Center shall have a unique thematic focus and be structured to test hypotheses that bridge basic and translational research in a synergistic and iterative fashion. Collectively, TBEL Centers will operate as a network that will inform future, rationally-design modes of intervention that are founded on strong biological mechanisms and be comprehensive, multi-dimensional, and appropriately tailored to the degree of malignant potential of an early lesion.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster OERWebmaster03@od.nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |